Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Benzinga · 3d ago
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.